Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

Company Overview - Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for chronic respiratory diseases with significant unmet medical needs [3] - The company's first commercial product, Ohtuvayre (ensifentrine), is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule [3] - Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory diseases [3] Financial Results Announcement - Verona Pharma will report its financial results for the fourth quarter and full year ended December 31, 2024, on February 27, 2025 [1] - An investment community conference call will be hosted at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update [1]